An Evaluation of a Social Network Intervention for Primary and Secondary Prevention of Opioid Overdoses

NCT ID: NCT04212364

Last Updated: 2024-01-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

614 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-15

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to pilot and implement a peer mentor intervention focused on overdose prevention and care.

The intervention consists of 3 sessions. During the first and second session, each participant will meet individually with a trained staff member. In the 3rd session, the participant will invite a social network member to attend the session, and these 2 participants will meet with a trained staff member.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The specific aims of the study are:

1. Conduct a pilot of an HIV/HCV/overdose prevention and care intervention for people who use opiates.
2. Evaluate the feasibility of collecting donated drug preparation containers (i.e., cookers) to assess the presence of fentanyl, HCV, and HIV.
3. Conduct a randomized controlled trial to assess efficacy of the experimental Peer Mentor condition on (a) overdose prevention and care education to drug network members, (b) naloxone availability, and (c) drug treatment readiness and entry.

There are two types of participants: Index participants and network participants. Both type of participant will currently used opiates. Participants will take part in a baseline visit and up to 3 follow-up visits. Index participants will be randomized into the intervention or control arm of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overdose

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Index participants will be randomized into 1 of two study arms.
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Peer Education

* During Session 1, participants will be trained in Peer Education and how to use Nasal Narcan. They will be given two Nasal Narcan kit that includes 2 doses. One kit if for their use and one kit is to give someone in their social network after they have trained them in how to use it.
* A week after Session 1, participants will be scheduled for Session 2.
* During session 1 and 2 participants, Index participants will be taught information and skills pertaining to overdose prevention and response and how to train network members in overdose prevention and response.
* At the 2nd session, index participants will be given 1 coupon to give to 1 member from their social network to attend Session 3.
* Session 3 will be a dyad session where Index participants will use their peer mentors' skills to train their network member in overdose prevention and response.
* Index participants will also be invited to up to 3 Booster Session (monthly) after they complete Sessions 1-3.

Group Type EXPERIMENTAL

Peer Education

Intervention Type BEHAVIORAL

In this intervention, people who use opiates will be trained to be peer educators.

Narcan Nasal Product

Intervention Type DRUG

All study participants will be trained in how to use nasal Narcan and they will receive a nasal Narcan kit.

Standard of care

* Participants randomized to this condition will participate in one 1-hour session. This session will be an individual session where the participant will meet with a trained staff member in a private room at the Lighthouse.
* This session will be standard overdose prevention and response information. Participants will also be trained in Narcan administration. Participants will be given 1 nasal Narcan kit.
* At the end of this session, participants will be asked to refer a network member to the study for survey visits

Group Type ACTIVE_COMPARATOR

Narcan Nasal Product

Intervention Type DRUG

All study participants will be trained in how to use nasal Narcan and they will receive a nasal Narcan kit.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Peer Education

In this intervention, people who use opiates will be trained to be peer educators.

Intervention Type BEHAVIORAL

Narcan Nasal Product

All study participants will be trained in how to use nasal Narcan and they will receive a nasal Narcan kit.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Experimental arm

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* self-reported use of opiates including heroin, fentanyl, or prescription opiates to get high at least 2 times in the last two weeks;
* willing to invite a network member who uses drugs to the study;
* ages 18-years or older;
* living in the Baltimore metropolitan region, and
* not previously enrolled in the study or currently enrolled in another Lighthouse study.


* self-reported use of illicit injecting or non-injecting opiates at least 2 times in the last two weeks;
* sees the Index participant 2 or more times in the past week;
* ages 18 years or older; and
* living in the Baltimore metropolitan region.

Exclusion Criteria

* Index participants may not take part in the study as a Network participant.
* Network participants may not take part in the study as an Index participant.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centers for Disease Control and Prevention

FED

Sponsor Role collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Carl A. Latkin, PhD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins Bloomberg School of Public Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Lighthouse Studies at Peer Point

Baltimore, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R01CE003021

Identifier Type: NIH

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Buprenorphine for Prisoners
NCT00574067 COMPLETED PHASE3